Ecofibre saw no growth in patent filings and highest growth of 1.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 1.99%. GlobalData’s DataBook provides a comprehensive analysis of Ecofibre’s patent filings and grants. Buy the databook here.
Ecofibre has been focused on protecting inventions in United States(US) with two publications in Q2 2024
The United States(US) Patent Office dominates the patent grants with nearly 100% of grants. The United States(US) patent Office are among the top ten patent offices where Ecofibre is filings its patents. Among the top granted patent authorities, Ecofibre has 100% of its grants in United States(US).
GW Research could be the strongest competitor for Ecofibre
Patents related to rare diseases lead Ecofibre's portfolio
Ecofibre has the highest number of patents in rare diseases. For rare diseases no patents were filed and 100% of patents were granted in Q2 2024.
Ovarian cancer related patents lead Ecofibre portfolio followed by leiomyoma, and endometrial cancer
Ecofibre has highest number of patents in ovarian cancer followed by leiomyoma, endometrial cancer, dysmenorrhea, and endometriosis.
For comprehensive analysis of Ecofibre's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.